

# We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index  
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?  
Contact [book.department@intechopen.com](mailto:book.department@intechopen.com)

Numbers displayed above are based on latest data collected.  
For more information visit [www.intechopen.com](http://www.intechopen.com)



---

# The Significance of Glutathione Conjugation in Aflatoxin Metabolism

---

Tahereh Ziglari and Abdolamir Allameh

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/52096>

---

## 1. Introduction

We all are exposed through air, food, drinks and skin contacts to harmful compounds throughout the period of our lifetime, including, a variety of pharmaceuticals and food-derived carcinogen metabolite (e.g. N-acetoxy-PhIP), [52], plant toxins (such as *glycoalkaloids* in nightshades<sup>1</sup>, *cyanogenic glucosides*<sup>2</sup>, or *pyrrolizidine alkaloids* in some herbs and herbal teas), xenobiotics<sup>3</sup> producing during early human pregnancy, fungal and bacterial toxins such as aflatoxins<sup>4</sup>; and cyanotoxin<sup>5</sup>; as well as free radicals and hydroperoxides. Many of these compounds are lipophilic and the organism can get rid of them only through metabolism.

Biotransformation has been conveniently categorized into three distinct phases, which act in a tightly integrated manner. Phases I and II enzymes catalyze the conversion of a lipophilic, non-polar xenobiotic into a more water-soluble and therefore less toxic metabolite, which can then be more easily excreted from the body. Phase I biotransformation seems to be enzymes that catalyzes oxidation, reduction or hydrolyze reactions, it usually converts substrates to more polar forms by introducing or unmasking a functional group (e.g., —OH, —NH<sub>2</sub>, or —SH). Phase I consist primarily of microsomal enzymes, which are found abundantly in the liver, gastrointestinal tract, lung and kidney, consisting of families and subfamilies of enzymes that are classified based on their amino acid sequence identities or similarities. [84]. Many of the enzymes like monooxygenases are found in the endoplasmic

---

1 - Plants like potatoes, tomatoes, peppers, egg plant, tobacco, some spices.

2 - Like bitter almond, cassava root, sorghum root, lima bean, fruit seed, etc.

3 - Chemical compounds foreign to the human organism without nutritional value

4 - A group of mycotoxins of which aflatoxin B1 is the most potent hepatocarcinogen

5 - A toxin producing by cyanobacteria of which microcystin-LR is predominant

reticulum membrane, but others such as the dehydrogenases for example alcohol dehydrogenases and peroxidases located in the cytoplasm, while still others such as monoamine oxidase are localized in mitochondria. Monooxygenases are also known as mixed function oxidases because in a typical reaction, one molecule of oxygen is consumed (reduced) per substrate molecule: one oxygen atom appearing in the product and the other in a molecule of water. The reaction scope of monooxygenases includes heteroatom oxidation, aromatic and aliphatic hydroxylation, epoxidation, and Baeyer-Villiger oxidation. There are two major types of microsomal monooxygenase, both of which require NADPH as an external reductant: the cytochrome P450 (CYP) system and flavin-containing monooxygenases. The mechanism of CYP is a complex cascade of individual steps involving the interaction of protein redox partners and consumption of reducing equivalents, usually in the form of NADPH. The iron heme containing enzyme, CYP, consists of two enzymes: NADPH-cytochrome P450 reductase and CYP. It is involved in the oxidative metabolism of many endogenous substances such as steroids and bile acids, as well as the detoxication of a wide variety of xenobiotics. It can oxidize AFB<sub>1</sub> to several products. Only one of these, the 8,9-exo-epoxide, appears to be mutagenic and the others are detoxification products. P4503A4, which can both activate and detoxicate AFB<sub>1</sub>, is found in the liver and the small intestine. [33], [52]. Flavincontaining monooxygenases catalyze an NADPH- and an oxygen-requiring oxidation of substances (primarily xenobiotics) bearing functional groups containing nitrogen, sulfur, or phosphorus. The properties of the CYPs electron transport systems have also been reported [77].

In detoxification pathway, a series of enzyme-catalyzed processes with broad specificities convert the toxic substances into less toxic metabolites by chemical reactions within the body. Although biotransformation reactions take place within cytoplasm and mitochondria but they mostly happen within endoplasmic reticulum (E.R). Cell types also differ in their biotransforming potential for example cells located near the major points of xenobiotic entry into the body such as liver, lung, and intestine possess greater concentrations of biotransforming enzymes than others [52].

Phase II conjugation reactions which generally act follow phase I activation consists of reactions in which metabolites containing appropriate functional groups are conjugated with substances such as glucuronate, glutamate, sulfate, reduced glutathione or uridine diphosphate (UDP)-glucuronic acid to finally discharge them through urine or bile. In general, conjugation dramatically improves solubility, which then promotes rapid excretion. Among the several types of conjugation reactions which are present in the body, including glucuronidation, sulfation, and glutathione and amino acid conjugation, glutathione which is catalyzed by glutathione S-transferases, is the major phase II reaction in many species [52]. With the exception of acetylation, methylation and fatty acid conjugation, the strategy of phase II biotransformation is to convert a xenobiotic to a more hydrophilic form via the attachment of a chemical moiety which is ionizable at physiological pH. This metabolic transformation also results in reduced affinity of the compound for its cellular target. [67], [23].

In animals, elimination of the soluble compounds from cells and excretion of biotransformed molecules from the body referred to as phase III. It has been suggested that the

phase III of detoxification system to be called antiporter activity. Antiporter activity is an important factor in the first pass metabolism of pharmaceuticals and other xenobiotics. The antiporter is an energy-dependent efflux pump, which pumps xenobiotics out of a cell, thereby decreasing the intracellular concentration of xenobiotics. In eukaryotic organisms, they are actively excreted or compartmentalized in the vacuole by ATP-dependent GS-X pumps [42], [27]. Indeed, as the glutathionylated moiety is hydrophilic, the conjugate cannot usually simply re-diffuse back into the cell [77]. Antiporter activity in the intestine appears to be co-regulated with intestinal phase I CYP3A4 enzyme. This observation suggests the antiporter may support and promote detoxification. Possibly, its function of pumping non-metabolized xenobiotics out of the cell and back into the intestinal lumen, may allow more opportunities for phase I activity to metabolize the xenobiotic before it is taken into circulation. Although, most literature on detoxification refers to liver enzymes, as the liver is the site of the majority of detoxification activity for both endogenous and exogenous compounds, however, the first contact the body with the majority of xenobiotics take places in the gastrointestinal tract. Intestinal mucosa possesses enzyme systems capable of various types of biotransformation of xenobiotics [52]. Among the detoxification pathways, glutathione conjugation pathway is the prominent route of AFB1 inactivation in liver of mammals. Depending on the availability of cellular GSH and the activation of glutathione S-transferase subclasses, detoxification of AFB1 is facilitated [24].

## 2. Glutathione


Glutathione is a ubiquitous thiol-containing isotriptide ( $\gamma$ -glu-cys-gly, FW 307.3), consisting of glycine, glutamic acid and cysteine molecules which was first discovered by Sir Fredrick Gowland Hopkins in 1920s, synthesized de novo in mammalian cells (Figure 1). This water soluble antioxidant compound is an unusual peptide in that the peptide bond between the glutamate residue and the cysteine residue is formed with the  $\gamma$ -carboxylate group of the former rather than the  $\alpha$ -carboxylate group. Today along with  $\beta$ -carotene, ascorbic acid (vitamin C),  $\alpha$ -tocopherol (vitamin E) and flavonoids *etc.*, GSH<sup>6</sup> is commonly referred to as an antioxidant [17], which neutralizes free radicals due to the high electron-donating capacity of its sulfhydryl (-SH) group, [13], and prevents damage to important cellular components, implicates in the cellular defense against xenobiotics. Glutathione status is a highly sensitive indicator of cell functionality and viability. Its levels in human tissues normally range from 0.1 to 10 mM, being most focused in liver (up to 10 mM) and in the spleen, kidney, lens, erythrocytes and leukocytes and its emptying be joined to a variety of diseases. Under normal conditions, glutathione is predominantly present in its reduced form, with only a small proportion present in its fully oxidized state [20].

Moreover, the GSH/GSSG<sup>7</sup> pair with their high reduction potential participates in maintaining other cellular thiol in a reduced state. Finally, GSH tends to a substrate or cofactor in some of

6 - Glutathione, reduced form

7 - Glutathione, oxidized state

GSH linked enzymes. There are a number of GSH linked enzymes that are involved in cellular protection against toxic substances. The glyoxalase I and II which are responsible for catalyzing the conversion of methylglyoxal (a by-product in glycolysis) to lactic acid are among these enzymes [76]. Glutathione reductase (GR) which catalyzes the reduction of GSSG using NADPH as a reductant is also a glutathione-linked enzyme involved in cell protection. GR is important to keep the high cellular reductive potential. Selenium dependent glutathione peroxidase are other GSH-linked enzymes that catalyze the reduction of peroxides using GSH as the reducing agent [7]. Finally, last but not the least, glutathione transferases are also GSH dependent enzymes with many properties among which catalyzing the conjugation of GSH to various electrophilic compounds is one of the most investigated function [25].



**Figure 1.** Structure of reduced glutathione; glutamate is linked in an isopeptide bond (via its  $\gamma$ -carboxyl group) to cysteine, which in turn forms a peptide linkage with glycine

### 3. Glutathione S-transferase

Glutathione S-transferases (GST, EC 2.5.1.18), which first discovered as enzymes in 1961 [12], are abundant proteins encoded by a highly divergent, ancient gene family. These major cellular detoxification enzymes present mostly in liver and kidney as well as intestine. In spite of 40 years of research the exact function of this protein is more complex than ever, but it has been found that these intracellular dimeric proteins, play a major role in the intracellular transport of endogenous compounds, metabolizes various electrophilic xenobiotics, ligand transport and thus protects cells against toxic effects [31], [87], [85]. GST catalyzes the conjugation of glutathione on the sulfur atom of cysteine to various electrophiles and catalyzes the conjugation of various electrophiles with GSH, detoxifying both exogenously and endogenously derived toxic compounds [13].

#### 3.1. Classification and structure

The superfamily of the glutathione transferases are divided into at least four major families of proteins, namely cytosolic or soluble GSTs, mitochondrial GSTs, microsomal GSTs and



bacterial fosfomycin-resistance proteins [39], [6], [69]. The cytosolic GSTs (cGSTs) have been subgrouped into numerous divergent classes on the basis of their chemical, physical and structural properties [39], [70]. The mitochondrial GSTs, also known as kappa class GSTs, are soluble enzymes that have been characterized in eukaryotes [65]. The third GST family comprises membrane-bound transferases called membrane-associated proteins involved in eicosanoid and glutathione metabolism, but these bear no similarity to soluble GSTs [44]. Representatives of all three families are also present in prokaryotes but the fourth family is found exclusively in bacteria [4]. The mammalian soluble GSTs are so far divided into eight classes based on their amino acid sequences including: Alpha ( $\alpha$ ), Kappa ( $\kappa$ ), Mu ( $\mu$ ), Omega ( $\omega$ ), Pi ( $\pi$ ), Sigma ( $\sigma$ ), Theta ( $\theta$ ) and Zeta ( $\zeta$ ), [11], [78], [64], [40]. GSTs are named using a letter corresponding to their class membership and Arabic numerals after the subunit composition (*e.g.* GST A1-1 is a homodimeric alpha class GST consisting of two subunit 1).

### 3.2. Presence of GST in cells

#### 3.2.1. Microbial GST

For a long time, GST enzymes from microbial sources were neglected and were not systematically studied. One of the reasons for this was the poor activity of microbial GSTs with CDNB<sup>8</sup> as a model substrate for GST activity, which led to the conclusion that these enzymes are rare in unicellular organisms [81], [77]. The first evidence for the presence of GSTs in bacteria was reported more 30 years ago by Takashi Shishido who showed the presence of GST activity in a strain of *Escherichia coli* [71]. Since then, GSTs have been found to be broadly distributed in aerobic prokaryotes, but not in anaerobic bacteria [59]. The absence of the enzyme in these microorganisms is consistent with the lack of GSH [28]. Bacterial glutathione transferases are part of a superfamily of enzymes that play a key role in cellular detoxification. Bacterial GSTs are implicated in a variety of distinct processes such as the biodegradation of xenobiotics, protection against chemical and oxidative stresses and antimicrobial drug resistance. In addition to their role in detoxification, bacterial GSTs are also involved in a variety of distinct metabolic processes such as the biotransformation of dichloromethane, the degradation of lignin and atrazine, and the reductive dechlorination of pentachlorophenol [4], [51].

#### 3.2.2. GSTs of fungi and yeasts

Until recently, relatively little was known about the presence and role of GST in fungi. However, expression of GST has been reported in some fungal species such as *Issatchenkia orientalis*, [73], *Phanerochaete chrysosporium*, *Yarrowia lipolytica*, *Mucor circinelloides* [70] *Schizosaccharomyces pombe*, *Aspergillus nidulans*, *Aspergillus parasiticus*, *Aspergillus flavus*, *Aspergillus fumigatus* [Burns et al., 2005] *Saccharomyces cerevisiae*, and *Cunninghamella elegans*, [70] [48] *etc.* However, the role of the enzyme in fungi, particularly toxigenic strains, is not well understood [2]. Although it has been shown that GST has a significant role in detoxifi-

---

8 - 1-chloro-2,4-dinitrobenzene

cation of aflatoxin and there is a possibility that this enzyme catalyses the conjugation of GSH to AFB<sub>1</sub>-epoxide to excrete its derivatives from the body, in 1988 and for the first time Saxena et al. reported that the relation of cytosolic GSH S-transferases from *A. flavus* to aflatoxin synthesis. In truth, they showed that in contrast to other cells that GST has a critical function to break down the aflatoxin, in aflatoxigenic *Aspergillus* spp., there is positive correlation between the GST activity and aflatoxin production [68], factors influencing aflatoxin formation such as growth period, medium etc., always enhanced GST activity in the toxigenic strain. Since the non-toxicogenic strain produces no aflatoxin, these factors have little effect on its GST activity. Our experience with GSH-conjugation system using inducers/inhibitors of aflatoxin metabolism in fungi also show a positive correlation of aflatoxin synthesis and GST activity in *Aspergillus* species [2], [88].

### 3.2.3. Plant GSTs

Plant GSTs are a family of multifunctional enzymes involved in the intracellular detoxification of xenobiotics and toxic compounds produced endogenously [54], [26]. Most of the enzymes are stress-inducible and play a role in the protection of plants from adverse effects of stresses. However, the activities of different GSTs have been detected and characterized in many plants, including maize, wheat, tobacco, soybean, barley, chickpea, peanut, sorghum, and sugarcane [20], [21], [22], [75].

### 3.2.4. Mammalian GST

The isoenzymes of glutathione transferase have been most widely studied in rat liver. Six basic transferases in rat liver have been characterized. In rabbit, GST catalyzes the conjugation of activated AFB<sub>1</sub> with glutathione. In an experiment to assess the abilities of lung and liver GSTs to conjugate AFB<sub>1</sub>-8, 9-epoxide, it has been shown that alpha-class and mu-class GSTs are of similar importance in catalyzing the reaction in the lung. The human glutathione S-transferase, possess both enzymatic and non-enzymatic functions and are involved in many important cellular processes, such as, phase II metabolism, stress response, cell proliferation, apoptosis, oncogenesis, tumor progression and drug resistance. The nonenzymatic functions of GSTs involve their interactions with cellular proteins, such as, Jun N-terminal kinase (JNK), tumor necrosis factor receptor-associated factor-2 (TRAF2), apoptosis-signal-regulating kinase 1 (ASK), serine/threonine kinases (PKA, PKC), and tissue transglutaminase 2 (TGM2), during which, either the interacting protein partner undergoes functional alteration or the GST protein itself is post-translationally modified and/or functionally altered [53], [74].

## 3.3. Different functions of GST

### 3.3.1. The metabolic function of GSTs

GSTs have been reported to involve in steroid metabolism by catalyzing the isomerization of  $\Delta^5$ -androstene-3, 17-dione to  $\Delta^4$ -androstene-3, 17-dione, and biosynthesis of prostaglandins. GST M2-2 is a prostaglandin E synthase in the brain cortex [8] and rat GST A1-1 and GST

A3-3 catalyze the reduction of  $\text{PGH}_2$  to  $\text{PGF}_2$ . The isomerization reaction of  $\text{PGF}_2$  to  $\text{PGD}_2$  is also catalyzed by sigma class of GST.  $\text{PGD}_2$ ,  $\text{PGE}_2$  and  $\text{PGF}_2$  act as hormones that bind to G-protein coupled receptors which regulate other hormones and neurotransmitters. Prostaglandin  $\text{D}_2$  and  $\text{E}_2$  are unstable and will easily be converted to prostaglandin  $\text{J}_2$  and  $\text{A}_2$ , respectively and their derivatives inhibit  $\text{NF}\kappa\text{B}$ , [66] a family of transcription factors that regulate the transcription of genes important for inflammatory processes. There are interesting speculations that GSTs might block other anti-inflammatory pathways by catalyzing the conjugation of GST to  $\text{PGJ}_2$  [38], [25]

### 3.3.2. The ligandin function of GSTs

Because of exhibiting a ligand binding function, glutathione transferases, have been known as ligandin, a function, which involves the noncovalent binding of nonsubstrate hydrophobic ligands such as heme, bilirubin, various steroids, and conceivably some lipophilic anticancer drugs as well. Although GSTs are generally viewed as playing a protective role in foreign compound metabolism, they can also catalyze reactions that lead to toxification. Examples include the GST dependent metabolism of 1,2-dibromoethane and related haloalkanes and probably also metabolism of the 6-thiopurine prodrug azathioprine [60], [5]. Similarly, the cytotoxicity of the polypeptide antibiotic neocarzinostatin is greatly enhanced by thiols such as GSH, although in this case there is no apparent requirement for GST catalysis [25], [18], [82].

### 3.3.3. The regulatory function of GSTs

In addition to above functions, GSTs also are responsible for interacting the proteins and enzymes. For example GST P1-1 interacts with c-Jun N-terminal kinase 1 (JNK1) suppressing the basal kinase activity. GST P1-1 also has a role in protection and cell survival after exposure to  $\text{H}_2\text{O}_2$  but not against UV-induced apoptosis [1]. Whereas, mouse GST M1-1 protects cells against both UV- and  $\text{H}_2\text{O}_2$ -induced cell death and binds to apoptosis signal-regulating kinase 1 (ASK1), inhibits its kinase activity [16]. Moreover, mouse GST A4-4 has also been proposed to interact with JNK and prevent cells from 4-hydroxynonenal induced apoptosis [15], [25].

### 3.3.4. The detoxification function of GSTs

As enzymes, GSTs are involved in many different detoxification reactions. They are commonly referred to as phase II enzymes. They catalyze the conjugation of GSH to a wide variety of endogenous and exogenous electrophilic toxic compounds. The GSH conjugates are excreted as mercapturic acids by the phase III metabolic pathway [41]. GST P1-1, GST M1-1 and GST A1-1 have been shown to catalyze the inactivation process of  $\alpha$ ,  $\beta$  unsaturated carbonyls like acrolein, (a cytotoxic compound present in tobacco smoke), propenals, (generated by oxidative damage to DNA) and alkenals, (formed by oxidative damage to lipids) [25], [70].



### 3.4. GST and aflatoxin

#### 3.4.1. Introduction

Study on GSTs of *Aspergillus flavus* stems from its ability to synthesize the aflatoxin. Aflatoxins are one of the major causes of liver cancer in certain regions of Africa and Asia [83], [61]. These secondary metabolites which primarily produced by some *Aspergillus* spp. are ubiquitous, and under favorable conditions can grow on a wide variety of agricultural commodities. Aflatoxins are major concern with to public health and the most important toxicological interest in aflatoxins has concentrated on aflatoxin B<sub>1</sub>, largely due to its acute toxicity and carcinogenicity in humans and animals. [3], [62], [88]. Genetic studies on aflatoxin biosynthesis in *A. flavus* and *A. parasiticus* has been led to the cloning of 25 clustered genes within a 70 kb DNA region responsible for the enzymatic conversions in the aflatoxin biosynthetic pathway [86].


#### 3.4.2. Primary metabolism of aflatoxin B<sub>1</sub>

Once inside the body and for toxicity to occur, AFB<sub>1</sub> undergoes enzymatic conversion to electrophilic endo and exo stereoisomers of AFB<sub>1</sub>-8,9-epoxide by the action of mixed function mono-oxygenase enzyme systems, CYPs are an intensively studied family of enzymes with currently approximately 4,000 known members. They have been found in almost all branches of the "tree of life", ranging from microorganisms over plants to mammals. CYP enzymes are classified into families identified by a number (e.g., 1, 2, 3, and 4), subfamilies identified by a letter (e.g., 2A, 2B, 2D, and 2E), and specific members identified by another number (e.g., CYP2E1 and CYP2A6) [47], [19].

In human, five CYP gene families, namely; CYP1, CYP2, CYP3, CYP4 and CYP7 are believed to play crucial roles in hepatic as well as extra-hepatic metabolism and elimination of xenobiotics [50], [58], [84]. This superfamily of hemoproteins aids in the oxidation of various substrates such as steroids, eicosanoids, pharmaceuticals, pesticides, pollutants, and carcinogens [57]. As mentioned earlier, they bioactivate AFB<sub>1</sub> to an electrophilic, highly reactive and unstable metabolite known as aflatoxin-8,9-epoxide, which binds to guanine residues in nucleic acids, leading to irreversible damage in DNA and causing hepatocarcinoma in humans, primates, and ducks [32], [84]. However, only AFB<sub>1</sub> exo-epoxide (AFBO), binds appreciably to DNA (Figure 2). The AFBO is highly unstable, and it reacts with cellular nucleophiles and can induce mutations by alkylating DNA, principally at the N<sup>7</sup> position of guanine forming the 8,9-dihydro- 8-(N<sup>7</sup>-guanyl)-9-hydroxy-AFB<sub>1</sub>. In addition, AFBO can bind to proteins and other critical cellular nucleophiles [43], [63]. Initial studies reported that concentrations of AFB<sub>1</sub> which are likely to be achieved in the liver following ingestion of "real-world" concentrations of AFB<sub>1</sub> are bioactivated to AFBO primarily by CYP1A2, whereas much higher concentrations are catalyzed by CYP3A4 [30], [46], [79]. A recent study demonstrated a dominant contribution of CYP3A4 homologues in AFBO production. AFB<sub>1</sub> metabolism studies in human liver microsomal preparations indicate a predominant role for CYP3A4 and that its expression level was an important determinant of the AFB<sub>1</sub> disposition in human liver [45]. Specific CYP3A4 inhibitors like troleandomycin have been shown to in-

hibit AFBO production [29], while inducers of CYP3A4 activity such as 3-methylcholanthrene and rifampicin, increase AFB<sub>1</sub> metabolism in cultured human hepatocytes [49].

CYP1A homologues also metabolize AFB<sub>1</sub> to produce the detoxified metabolite AFM<sub>1</sub>, whereas CYP3A enzymes<sup>9</sup>, produce another detoxified metabolite, aflatoxin Q<sub>1</sub> (AFQ<sub>1</sub>), the major metabolite of AFB<sub>1</sub> (Figure 2). [33]. Although both CYP1A and CYP3A isoforms oxidize AFB<sub>1</sub>, there are conflicting reports on their relative importance [63].



**Figure 2.** Bioactivation of AFB<sub>1</sub> to exo and endo-epoxides and subsequent GST-catalyzed conjugation with GSH.

CYPs may also catalyze demethylation to aflatoxin P (AFP<sub>1</sub>) of the parent AFB<sub>1</sub> molecule, resulting in products less toxic than AFB<sub>1</sub>. Other major metabolites in the human include aflatoxicol (AFL), AFLH<sub>1</sub>, AFB<sub>2</sub>á and AFB<sub>1</sub>-2, 2-dihydrodiol [80].

### 3.4.3. Secondary metabolism of aflatoxin B<sub>1</sub>

Oxidative metabolism of AFB<sub>1</sub> by cytochrome P450 results in the formation of several products such as AFB<sub>1</sub>-epoxide which serve as substrates for phase II detoxification enzymes. Phase II enzymes such as GSTP1 and GSTA1, found in several mammalian species and non-tumorous liver tissues [14] are the first step in the mercapturic acid pathway, which leads to the excretion of the xenobiotics. Because conjugation of the electrophilic AFB<sub>1</sub>-8,9-epoxide with GSH is an alternative fate to binding to nucleophilic centers in cellular macromolecules, GSTs play a critical role in the protection of tissues from the deleterious effects of bio-activated AFB<sub>1</sub>, and tissues vary considerably in both GST concentration and distribution of specific GST isoforms. Two stereoisomers of AFB<sub>1</sub>-8,9-epoxide were identified: AFB<sub>1</sub> exo-epoxide and AFB<sub>1</sub> endo-epoxide, and their corresponding GSH conjugates; AFB<sub>1</sub> exo-epoxide-GSH and AFB<sub>1</sub> endo-epoxide-GSH. It has been reported that only the exo-epoxide effectively interacts with DNA and was at least 500-fold more potent as a mutagen than the endo stereoisomer. [43], [72].

Throughout the animal kingdom, significant variations exist in the susceptibility of different species to AFB<sub>1</sub>. Man and rats are sensitive to AFB<sub>1</sub> but mice can tolerate this mycotoxin. [35]. In man and rat as well as many mammalian species, AFB<sub>1</sub>-8,9-epoxide is efficiently conjugated with reduced glutathione. Little is known about the identity of the GST which is responsible for detoxifying activated AFB<sub>1</sub>. To date, the catalytic conjugation of AFB<sub>1</sub>-8,9-epoxide has only been reported using rat and mouse GST as enzyme source and the ability of GST in other species to catalyze this reaction has not been described. In the investigation on hepatic rat GST responsible for catalyzing the conjugation of AFB<sub>1</sub>-8,9-epoxide with GSH, it has been shown that the alpha class but not mu-class of GST possess greatest ability to metabolize activated AFB<sub>1</sub>. Although the rat pi-class GST cannot catalyze this reaction it might be expected that the theta-class enzyme GST is active towards AFB<sub>1</sub>-8,9-epoxide. By contrast with the rat, the mouse exhibits high constitutive levels of GST activity towards AFB<sub>1</sub>-8,9-epoxide and alpha-class GST in Swiss-Webster mice possess high activity towards AFB<sub>1</sub>-8,9-epoxide and can protect against DNA-binding by AFB<sub>1</sub> metabolites. Neither the murine mu-class nor pi-class GST can detoxify activated AFB<sub>1</sub> and all the activity towards this substrate is contributed by the alpha-class GST. It can be concluded that in the mouse the theta-class enzymes do not play a major role in the detoxification of activated AFB<sub>1</sub>. Hamster liver contains significant levels of AFB<sub>1</sub>-GSH-conjugating activity but the GST involved have not been characterized. In human liver, GST does not appear to play as important a role in providing protection against AFB<sub>1</sub> as the rodent GST. The *in vitro* studies have suggested that in comparison with rodents, relatively little AFB<sub>1</sub>-GSH conjugate is produced by human liver, but insufficient data exist to be certain that this reaction is not of physiological importance in man, particularly as an aflatoxin mercapturate has been detected in the urine of marmoset monkeys treated with AFB<sub>1</sub>. The ability of human alpha-class

GST to detoxify activated AFB<sub>1</sub> has not been examined systematically. Three separate alpha-class isoenzymes, which represent the dimeric combinations of two distinct subunits (B1 & B2) have been described in human liver. Furthermore, it is not known whether man possesses inducible GST and if so, whether these might be involved in AFB<sub>1</sub> metabolism [34]. Nevertheless, it has been shown that in the humans, the GST with the highest activity toward AFB<sub>1</sub> exo-epoxide is the polymorphic hGSTM1-1 which is absent in about 50% of individuals in most human populations. This suggests that AFB<sub>1</sub>-epoxide individuals lacking the beneficial effects of hGSTM1-1 may be at elevated risk. Indeed some reports suggest that the GSTM1 genetic polymorphism may affect AFB<sub>1</sub> detoxification in human liver. In contrast to the liver, the lung is composed of many different cell types and expression of GSTs in different human lung cell types is heterogenous. Thus certain cell types with low levels of GSTs or lacking specific GST isoforms may be at higher risk of AFB<sub>1</sub> toxicity [72]. GSTP was also demonstrated to significantly increase in early hepatocarcinogenesis and hepatocellular carcinoma compared to their adjacent normal tissues. Loss of GSTP1 has been suggested to increase the risk of DNA damage and mutation. Moreover, up-expression of GSTA was suggested to protect liver cells against oxidative stress via an extracellular signal-regulated kinases (ERKs) and p38 kinase (p38K)-related pathway, as well as through the inhibition of H<sub>2</sub>O<sub>2</sub>-induced apoptosis to inhibit reactive oxygen species (ROS)- induced lipid peroxidation. It was suggested that inactivated or down-regulated GSTP1 and GSTA1 genes could increase genomic damage when individuals were exposed to carcinogens. [14]. GSTs have also been shown to exhibit GSH-dependent peroxidase activity and thus may be involved in resistance to oxidative stress. Cytosolic GSTs have been identified in almost all organisms, with mammalian GSTs the most clearly characterized [Burns et al. 2005].

Besides the formation of GSH conjugates, glucuronide and sulfate conjugates of AFB<sub>1</sub> have also been described in a variety of species including rat, mouse, monkey and trout. The ability to form these alternative secondary metabolites may be of considerable physiological importance in species, like the trout, that are unable to produce AFB<sub>1</sub>-GSH conjugates. Before AFB<sub>1</sub> can form glucuronide and sulfate conjugates it requires to be hydroxylated. The primary metabolites AFM<sub>1</sub>, AFP<sub>1</sub>, and AFQ<sub>1</sub> can readily form glucuronide or sulfate conjugates. Whilst such conjugation reactions may aid excretion of aflatoxin, their toxicological value is unclear as such hydroxylated metabolites are not particularly harmful because they are not subject to 8,9-epoxidation. However, it has been proposed that AFB<sub>1</sub> is itself capable of forming glucuronide and sulfate conjugate; these reactions might entail a molecular rearrangement possibly involving the addition of water to the keto group in the cyclopentone ring, that result in the introduction of a hydroxyl group into the AFB<sub>1</sub> structure. This proposal is of particular interest as it enables the direct detoxification of AFB<sub>1</sub> through reactions that may not involve cytochrome P450. These workers have also proposed that amines, thiols and alcohols might also be conjugated to AFB<sub>1</sub> via the keto group in the cyclopentone ring [34].

Alternatively, the AFB<sub>1</sub>-epoxide can hydrolyse spontaneously to AFB<sub>1</sub>-dihydrodiol. This is not a true detoxification process as the dihydrodiol product can rearrange at neutral pH values to form a dialdehydic phenolate ion. This AFB<sub>1</sub>-dialdehyde can undergo Schiff-base formation with primary amine groups in proteins and is therefore likely to be cytotoxic.



Recently, a novel AFB<sub>1</sub>-aldehyde reductase (AFB<sub>1</sub>-AR) purified from ethoxyquin (EQ)-treated rat liver has been shown to metabolize the dialdehyde form of AFB<sub>1</sub>-dihydrodiol to an AFB<sub>1</sub>-dialcohol and its relative importance in AFB<sub>1</sub> detoxification may be considerable [35]. The toxicity of AFB<sub>1</sub> is selective towards certain species. In contrast with the mouse and hamster, the rat, guinea pig and man are susceptible to the hepatotoxic effects of AFB<sub>1</sub> [34]. The toxicity of the mycotoxin is based on a balance between the rate of primary activation of AFB<sub>1</sub> and the rate of detoxification of primary metabolites or repair of cellular damage, determined by the relative activity of enzymes responsible for these reactions; the differential toxicity of AFB<sub>1</sub> between species is thought to be due mainly to different levels of activity of xenobiotic-metabolizing enzymes. In this regard, the livers of mice which are resistant to the hepatotoxic effects of AFB<sub>1</sub> contain high concentrations of a Yc-type GST subunit [55] that has considerable GSH conjugating activity towards AFB<sub>1</sub>-epoxide [34], [37], [10], [9]. By contrast, the Fischer rat, an inbred strain that is five times more susceptible to AFB<sub>1</sub>-induced liver cancer than the Wistar rat [34], possesses 20-fold less hepatic AFB<sub>1</sub>-GSH-conjugating activity than the mouse. Fischer rats can, however, be protected against AFB<sub>1</sub> by treatment with the antioxidant EQ. It has shown that following EQ-treatment the livers of Fischer rats express a GST subunit that is immunochemically related to the mouse Yc subunit [35]. Moreover, this inducible polypeptide (Yc2, subunit 10) has high activity towards AFB<sub>1</sub>-epoxide [35]. Thus, the Yc2 subunit is thought to confer protection against AFB<sub>1</sub>, and its induction by EQ is likely to be one of the key mechanisms for the protective action of this anti-carcinogen [56].

The transport of foreign compounds out of cells can be achieved by at least two distinct families of efflux pump, both of which may provide protection against AFB<sub>1</sub> by helping eliminate the mycotoxin from target cells. The best characterized of these two pumps is P-glycoprotein, the product of the *mdr 1* gene which has been studied extensively because of its involvement in acquired resistance to anticancer drugs. The other pump is the glutathione S-conjugate carrier which is responsible for the transport of endogenous compounds such as oxidized glutathione and leukotriene C<sub>4</sub> as well as glutathione conjugates of foreign compounds an example of which might be S-(2,4-dinitrophenyl)glutathione. Both pump systems are ATP-dependent and are inhibited by vanadate but differ in that P-glycoprotein appears to have specificity towards hydrophobic compounds whereas the glutathione S-conjugate carrier is as its name suggests specific for leukotrienes and drug-glutathione conjugates. Although it is not known whether P-glycoprotein is able to transport AFB<sub>1</sub> the broad specificity of this efflux pump and its activity towards hydrophobic drugs suggests that this is likely. It also appears highly probable that the glutathione S-conjugate carrier is responsible for the transport of AFB<sub>1</sub> conjugated with GSH. Both P-glycoprotein and the glutathione S-conjugate carrier are expressed in the liver which is compatible with the hypothesis that these pumps could be involved in the efflux of AFB<sub>1</sub> and its metabolites. The involvement of P-glycoprotein in AFB<sub>1</sub> transport is supported by the fact that aflatoxin has been shown to induce mRNA encoding this protein in mouse liver. [36].

Relatively little is known about the enzymes responsible for the removal of AFB<sub>1</sub> that is bound covalently to DNA in mammalian cells. Exposure of cells to AFB<sub>1</sub> results in the formation of three major adducts. Of these, trans-2,3-dihydro-2-(N<sup>7</sup>-guanyl)-3-hydroxy AFB<sub>1</sub>



(AFB<sub>1</sub>-N<sup>7</sup>G) is the most abundant. It is chemically unstable and is lost spontaneously from DNA *in vitro* to yield apurinic sites. The other two adducts, 2,3-dihydro-2-(N-formyl-2,3,6-triamino-4-oxopyrimidine-N-yl)-3-hydroxy AFB<sub>1</sub> and 8,9-dihydro-8-(2-amino-6-formamido-4-oxo-3,4-dihydropyrimidin-5-yl formamido)-9-hydroxy AFB<sub>1</sub> (AFB<sub>1</sub>-FAPY and AFB<sub>1</sub>III respectively) are not spontaneously but appear to be removed catalytically by DNA repair enzymes. The loss of AFB<sub>1</sub>-DNA adducts *in vivo* is biphasic and this occurs through two distinct mechanisms. Following exposure to AFB<sub>1</sub>, all adduct species are removed rapidly until less than 1000 adducts per cell remain. Once this point is reached the AFB<sub>1</sub>-FAPY and AFB<sub>1</sub>III adducts are no longer removed and only AFB<sub>1</sub>-N<sup>7</sup>G is lost but at a much slower rate from the cell [36].

### 3.4.4. Conclusion and future directions

Evidences presented in this review article clearly show that glutathione conjugation to aflatoxin metabolites which has been detected in aflatoxin-producing fungi as well as liver tissues of mammals play a crucial role in reducing the interaction of aflatoxins with cellular macromolecules. However further studies is needed to answer the main questions about the contribution of glutathione conjugation system in removing aflatoxin in different cellular systems. The future direction of this topic is to find out experimental-based answers to the following questions:

1. What is the relationship between the rate of aflatoxin metabolism and the level of aflatoxin-GSH conjugate formation?
2. Which classes of glutathione S-transferases in each cellular system is directly responsible for involvement of aflatoxin-GSH conjugate formation
3. What is the relationship between the efficiency of glutathione conjugation system and toxic action of aflatoxins in different cell systems.

## Acknowledgements

It is the time to express the deepest gratitude to Mr. Hamed Foroozesh for whole-hearted support and for his devoted care. Thanks for his vast knowledge and skill in many areas and his assistance.

## Author details

Tahereh Ziglari<sup>1\*</sup> and Abdolamir Allameh<sup>2</sup>

\*Address all correspondence to: Tz\_572@usc.edu

1 Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, California, USA

2 Department of Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, I.R. Iran

## References

- [1] Adler, V., Yin, Z., Fuchs, S. Y., Benezra, M., Rosario, L., Tew, K. D., Pincus, M. R., Sardana, M., Henderson, C. J., Wolf, C. R., Davis, R. J., & Ronai, Z. (1999). Regulation of JNK signaling by GSTp. *EMBO J.*, 18, 1321-34.
- [2] Allameh, A., Razzaghi-Abyaneh, M., Shams, M., Rezaee, M. B., & Jaimand, K. (2002). Effect of neem leaf extract on production of aflatoxins and activities of fatty acid synthetase, isocitrate dehydrogenase, and glutathione S-transferase in *Aspergillus parasiticus*. *Mycopathologia*, 154, 79-84.
- [3] Allameh, A. A., Ziglari, T., & Rasooli, I. (2011). Phytoinhibition of growth and aflatoxin biosynthesis in toxigenic fungi. *Chapter 15 in the book: aflatoxin, detection, measurement and control. InTech publication*, 978-9-53307-711-6.
- [4] Allocati, N., Federici, I., Masulli, M., & Dillio, C. (2009). Glutathione transferases in bacteria. *The FEBS Journal*, 276, 58-75.
- [5] Anders, M. W., Lash, L., Dekant, W., Elfarra, A. A., & Dohn, D. R. (1988). Biosynthesis and biotransformation of glutathione S-conjugates to toxic metabolites. *Crit. Rev. Toxicol.*, 18(4), 311-341.
- [6] Armstrong, R. N. (2000). Mechanistic diversity in a metalloenzyme superfamily. *Biochemistry*, 39, 13625-13632.
- [7] Arthur, J. R. (2000). The glutathione peroxidases. *Cell. Mol. Life Sci.*, 57, 1825-35.
- [8] Beuckmann, C. T., Fujimori, K., Urade, Y., & Hayaishi, O. (2000). Identification of mu-class glutathione transferases M2-2 and M3-3 as cytosolic prostaglandin E synthases in the human brain. *Neurochem. Res.*, 25(5), 733-8.
- [9] Beutler, T. M., & Eaton, D. L. (1992a). Complementary DNA cloning, messenger RNA expression and induction of alpha-class glutathione S-transferases in mouse tissues. *Cancer Res*, 52, 314-318.
- [10] Beutler, T. M., Slone, D., & Eaton, D. L. (1992b). Comparison of the aflatoxin B1-8,9-epoxide conjugating activities of two bacterially expressed alpha class glutathione S-transferase isozymes from mouse and rat. *Biochem. Biophys. Res. Commun*, 188(2), 597-603.
- [11] Board, P. G., Coggan, M., Chelvanayagam, G., Easteal, S., Jermini, L. S., Schulte, G. K., Danley, D. E., Hoth, L. R., Griffor, M. C., Kamath, A. V., Rosner, M. H., Chrunky,

- B. A., Perregaux, D. E., Gabel, C. A., Geoghegan, K. F., & Pandit, J. (2000). Identification, Characterization, and Crystal Structure of the Omega Class Glutathione Transferases. *Journal of Biological Chemistry*, 275(32), 24798-24806.
- [12] Booth, J., Boyland, E., & Sims, P. (1961). An enzyme from rat liver catalyzing conjugations with glutathione. *Biochem. J.*, 79, 516-24.
- [13] Cancado, G. M. A., De Rosa Jr, V. E., Fernandez, J. H., Maron, L. G., Jorge, R. A., & Menossi, M. (2005). Glutathione S-transferase and aluminum toxicity in maize. *Functional Plant Biology*, 32, 1045-1055.
- [14] Chen, Y. I., Tseng, H. S., Kuo, W. H., Yang, S. F., Chen, D. R., & Tsai, H. T. (2010). Glutathione S-Transferase P1 (GSTP1) gene polymorphism increases age-related susceptibility to hepatocellular carcinoma. *BMC Medical Genetics*, 11, 46.
- [15] Cheng, J. Z., Singhal, S. S., Sharma, A., Saini, M., Yang, Y., Awasthi, S., Zimniak, P., & Awasthi, Y. C. (2001). Two distinct 4-hydroxynonenal metabolizing glutathione S-transferase isozymes are differentially expressed in human tissues. *Biochem. Biophys. Res. Commun.*, 282, 1268-74.
- [16] Cho, S. G., Lee, Y. H., Park, H. S., Ryoo, K., Kang, K. W., Park, J., Eom, S. J., Kim, M. J., Chang, T. S., Choi, S. Y., Shim, J., Kim, Y., Dong, M. S., Lee, M. J., Kim, S. G., Ichijo, H., & Choi, E. J. (2001). Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1. *J. Biol. Chem.*, 276(16), 12749-55.
- [17] Cotgreave, I. A., & Gerdes, R. G. (1998). Recent trends in glutathione biochemistry-glutathione-protein interactions: a molecular link between oxidative stress and cell proliferation? *Biochem Biophys Res Commun*, 242, 1-9.
- [18] De Graff, W. G., Russo, A., & Mitchell, J. B. (1985). Glutathione depletion greatly reduces neocarzinostatin cytotoxicity in Chinese hamster V79 cells. *J. Biol. Chem*, 260, 8312-5.
- [19] Diaz, G. J., Murcia, H. W., & Cepeda, S. M. (2010). Cytochrome P450 enzymes involved in the metabolism of aflatoxin B1 in chickens and quail. *Poultry Science association Inc*, 89, 2461-2469.
- [20] Dixon, D. P., Cummins, L., Cole, D. J., & Edwards, R. (1998). Glutathione-mediated detoxification systems in plants. *Current opinion in Plant Biology*, 258-266.
- [21] Dixon, D. P., Laphorn, A., & Edwards, R. (2002). Plant glutathione transferases. *Genome Biol*, 3(3), 1-10.
- [22] Dixon, D. P., Mc Ewen, A. G., Laphorn, A. J., & Edwards, R. (2003). Forced evolution of a herbicide detoxifying glutathione transferase. *J. Biol. Chem.*, 278(26), 23930-23935.
- [23] Dusinska, M., Staruchova, M., Horska, A., Smolkova, B., Collins, A., Bonassi, S., & Volkovova, K. (2012). Are glutathione S-transferases involved in DNA damage signalling? Interactions with DNA damage and repair revealed from molecular epi-

demology studies. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*. In press.

- [24] Eaton, D. L., & Gallagher, E. P. (1994). Mechanisms of aflatoxin carcinogenesis. *Annu. Rev. Pharmacol. Toxicol.*, 34, 135-172.
- [25] Edalat, M. (2002). Multiple functions of glutathione transferase. *Dissertation for the Degree of Doctor of Philosophy in Biochemistry presented at Uppsala University*.
- [26] Edwards, R., Dixon, D. P., & Walbot, V. (2000). Plant glutathione S-transferase: enzymes with multiple functions in sickness and in health. *Trends Plant Sci.*, 5(5), 193-198.
- [27] Ernst, R., Klemm, R., Schmitt, L., Kuchler, K., & Helmut, Sies. L. P. (2005). Yeast ATP-Binding Cassette Transporters: Cellular Cleaning Pumps. *Methods in Enzymology*, 400, 460-484.
- [28] Fahey, R. C. (2001). Novel thiols of prokaryotes. *Annual Review of Microbiology*, 55, 333-356.
- [29] Gallagher, E. P., Wienkers, L. C., Stapleton, P. L., Kunze, K. L., & Eaton, D. L. (1994). Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B<sub>1</sub>. *Cancer Research*, 54, 101-108.
- [30] Gallagher, E. P., Kunze, K. L., Stapleton, P. L., & Eaton, D. L. (1996). The kinetics of aflatoxin B<sub>1</sub> oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. *Toxicology and Applied Pharmacology*, 141, 595-606.
- [31] George, S. G. (1994). Enzymology and molecular biology of phase II xenobiotic conjugating enzymes in fish. *Aquatic toxicology, molecular biochemical and cellular perspectives* (Eds.: D.C. Malins and G.K.Ostrander). Lewis Publishers, Ann Arbor., 27-86.
- [32] Guengerich, F. P., Gillam, E. M., & Shimada, T. (1996a). New applications of bacterial systems to problems in toxicology. *Critical Reviews in Toxicology*, 26, 551-583.
- [33] Guengerich, F. P., Johnson, W. W., Ueng, Y. F., Yamazaki, H., & Shimada, T. (1996b). Involvement of Cytochrome 450Glutathione S-Transferase, and Epoxide Hydrolase in the Metabolism of Aflatoxin B<sub>1</sub> and Relevance to Risk of Human Liver Cancer. *Environment Health Perspectives*, 104, 557-562.
- [34] Hayes, J. D., Judah, D. J., McLellan, L. I., & Neal, G. E. (1991a). Contribution of the glutathione S-transferases to the mechanisms of resistance to aflatoxin B<sub>1</sub>. *Pharmacol. Ther.*, 50, 443-472.
- [35] Hayes, J. D., Judah, D. J., Mc Lellan, L. I., Kerr, L. A., Peacock, S. D., & Neal, G. E. (1991b). Ethoxyquin-induced resistance to aflatoxin B<sub>1</sub> in the rat is associated with the expression of a novel alpha-class glutathione S-transferase subunit, Yc2, which possesses high catalytic activity for aflatoxin B<sub>1</sub>-8,9-epoxide. *Biochem. J.*, 279, 385-398.

- [36] Hayes, J. D., Judah, D. J., Mc Lellan, L. I., & Neal, G. E. (1991c). Contribution of the glutathione S-transferases to the mechanisms of persistence to aflatoxin B1. *Pharmac. Ther.*, 50, 443-472.
- [37] Hayes, J. D., Judah, D. J., Neal, G. E., & Nguyen, T. (1992). Molecular cloning and heterologous expression of a cDNA encoding a mouse glutathione S-transferase Yc subunit possessing high catalytic activity for aflatoxin B1-8,9-epoxide. *Biochem. J.*, 285, 173-180.
- [38] Hayes, J. D., & Strange, R. C. (2000). Glutathione S-transferase polymorphisms and their biological consequences. *Pharmacology*, 61(3), 154-66.
- [39] Hayes, J. D., Flanagan, J. U., & Jowsey, I. R. (2005). Glutathione transferases. *Annu Rev Pharmacol Toxicol*, 45, 51-88.
- [40] Hu, B., Deng, L., Wen, C., Yang, X., Pei, P., Xie, Y., & Luo, S. (2012). Cloning, identification and functional characterization of a pi-class glutathione S-transferase from the freshwater mussel *Cristaria plicata*. *Fish & Shellfish Immunology*, 32(1), 51-60.
- [41] Ishikawa, T. (1992). ATP dependent glutathione S-conjugate transport pump. *Trends Biochem. Sci*, 17, 463-8.
- [42] Ishikawa, T., Li, Z. S., Lu, Y. P., & Rea, P. A. (1997). The GS-X pump in plant, yeast, and animal cells: Structure, function, and gene expression. *Bioscience Reports*, 17, 189-207.
- [43] Iyer, R., Coles, B., Raney, K. D., Thier, R., Guengerich, F. P., & Harris, T. M. (1994). DNA adduction by the potent carcinogen aflatoxin B1: mechanistic studies. *Journal of the American Chemical Society*, 116, 1603-1609.
- [44] Jakobsson, P. J., Morgenstern, R., Mancini, J., Ford-Hutchinson, A., & Persson, B. (1999). Common structural features of MAPEG- a widespread superfamily of membrane-associated proteins with highly divergent functions in eicosanoid and glutathione metabolism. *Protein Sci*, 8, 689-692.
- [45] Kamdem, L. K., Meineke, I., Godtel-Armbrust, U., Brockmoller, J., & Wojnowski, L. (2006). Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. *Chemical Research in Toxicology*, 19, 577-586.
- [46] Kelly, J. D., Eaton, D. L., Guengerich, F. P., & Coulombe Jr, R. A. (1997). Aflatoxin B1 activation in human lung. *Toxicology and Applied Pharmacology*, 144, 88-95.
- [47] Klaassen, C. D. (2001). Casarett and Doull's Toxicology: The Basic Science of Poisons. 6th ed. McGraw-Hill, New York, N.Y.
- [48] Krajewski, M. P., Kanawati, B., Fekete, A., Kowalski, N., Schmitt-Kopplin, P., & Grill, E. (2012). Analysis of Arabidopsis glutathione-transferases in yeast. *Phytochemistry In Press*.
- [49] Langouet, S., Coles, B., Morel, F., Becquemont, L., Beaune, P., Guengerich, F. P., Ketterer, B., & Guillouzo, A. (1995). Inhibition of CYP1A2 and CYP3A4 by oltipraz re-



- sults in reduction of aflatoxin B1 metabolism in human hepatocytes in primary culture. *Cancer Research*, 55, 5574-5579.
- [50] Lewis, D. E. (2003). P450 structures and oxidative metabolism of xenobiotics. *Pharmacogenomics*, 4, 387-395.
- [51] Li, C., Su, X., Li, Y., Li, T., Sun, C., Zhou, T., & Liu, H. (2012). Two classes of glutathione S-transferase genes with different response profiles to bacterial challenge in *Venerupis philippinarum*. *Fish & Shellfish Immunology*, 32(1), 219-222.
- [52] Liska, D. J. (1998). The detoxification enzyme system. *Alternative Medicine Review*, 3(3), 187-198.
- [53] Lo, H. W., & Ali-Osman, F. (2007). Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. *Current Opinion in Pharmacology*, 7, 367-374.
- [54] Mannervik, B., & Danielson, U. H. (1988). Glutathione transferases structure and catalytic activity. *Crit. Rev. Biochem.*, 23(2), 283-337.
- [55] Mc Lellan, L. I., Kerr, L. A., Cronshaw, A. D., & Hayes, J. D. (1991). Regulation of mouse glutathione S-transferases by chemoprotectors. Molecular evidence for the existence of three distinct alpha-class glutathione S-transferase subunits, Ya1, Ya2, and Ya3, in mouse liver. *Biochem. J.*, 276, 461-469.
- [56] Mc Lellan, L., Judah, D. J., Neal, G. E., & Hayes, J. D. (1994). Regulation of aflatoxin B1-metabolizing aldehyde reductase and glutathione S-transferase by chemoprotectors. *Biochem. J.*, 300, 117-124.
- [57] Parikh, A., Gillam, E. M., & Guengerich, F. P. (1997). Drug metabolism by *Escherichia coli* expressing human cytochromes P450. *Nature Biotechnology*, 15, 784-788.
- [58] Pascussi, J. M., Gerba-Chaloin, I. S., Drocourt, L., Maurel, P., & Vilarem, M. J. (2003). The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. *Biochim. Biophys. Acta*, 1619, 243-253.
- [59] Piccolomini, R., Aceto, A., Allocati, N., Faraone, A., & Di Ilio, C. (1991). Purification of a GSH-affinity binding protein from *Bacteroides fragilis* devoid of glutathione transferase activity. *FEMS Microbiol Lett*, 82, 101-106.
- [60] Pickett, C. B. (1989). Glutathione S-transferases. Gene structure, regulation, and biological function. *Annu. Rev. Biochem*, 58, 743-764.
- [61] Razzaghi-Abyaneh, M., Allameh, A., & Shams, M. (2000). Screening of aflatoxin-producing mould isolates based on fluorescence production on a specific medium under ultraviolet light. *Acta Medica Iranica*, 38, 67-73.
- [62] Razzaghi-Abyaneh, M., Shams-Ghahfarokhi, M., Allameh, A., Kazeroon-Shiri, M., Ranjbar-Bahadori, S., Mirzahoseini, H., & Rezaee, M. B. (2006a). A survey on distribution of *Aspergillus* section *Flavi* in corn field soils in Iran: population patterns

based on aflatoxins, cyclopiazonic acid and sclerotia production. *Mycopathologia*, 161, 183-192.

- [63] Rawal, S., Kim, J. E., & Jr, R. C. (2010). Aflatoxin B1 in poultry: Toxicology, metabolism and prevention. *Research in Veterinary Science*, 89, 325-331.
- [64] Revathy, K. S., Umasuthan, N., Lee, Y., Choi, C. Y., Whang, I., & Lee, J. (2012). First molluscan theta-class glutathione S-transferase: Identification, cloning, characterization and transcriptional analysis post immune challenges. *Biochemistry and Molecular Biology*, 162(1-3), 10-23.
- [65] Robinson, A., Huttley, G. A., Booth, H. S., & Board, P. G. (2004). Modelling and bioinformatics studies of the human kappa-class glutathione transferase predict a novel third glutathione transferase family with similarity to prokaryotic 2-hydroxychromene-2-carboxylate isomerases. *Biochem J.*, 379, 541-552.
- [66] Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000). Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. *Nature*, 403, 103-8.
- [67] Sacco, J. C. (2006). Phase II biotransformation of xenobiotics in polar bear (*Ursus maritimus*) and channel catfish (*Ictalurus punctatus*). *A dissertation presented to the graduate school of the University of Florida in partial fulfillment of the requirements for the degree of doctor of philosophy.* Waxman.
- [68] Saxena, M., Mukerji, K. G., & Raj, H. G. (1988). Positive correlation exists between glutathione S-transferase activity and aflatoxin formation in *Aspergillus flavus*. *Biochem J*, 245, 567-70.
- [69] Scarcella, S., Lamenza, P., Virkel, G., & Solana, H. (2012). Expression differential of microsomal and cytosolic glutathione S-transferases in *Fasciola hepatica* resistant at triclabendazole. *Molecular and Biochemical Parasitology*, 181(1), 37-39.
- [70] Sheehan, D., Meade, G., Foley, V. M., & Dowd, CA. (2001). Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily. *Biochemical Journal*, 360, 1-16.
- [71] Shishido, T. (1981). Glutathione S-transferase from *Escherichia coli*. *Agric Biol Chem*, 45, 2951-2953.
- [72] Stewart, R. K., Serabjit-Singh, C. J., & Massey, T. E. (1996). Glutathione S-Transferase-Catalyzed Conjugation of Bioactivated Aflatoxin B1 in Rabbit Lung and Liver. *Toxicology and Applied Pharmacology*, 140, 499-507.
- [73] Tamaki, H., Yamamoto, K., & Kumagai, H. (1999). Expression of two glutathione S-transferase genes in the yeast *Issatchenkia orientalis* is induced by o-dinitrobenzene during cell growth arrest. *J. Bacteriol.*, 181, 2958-2962.

- [74] Tew, K. D., Manevich, Y., Grek, C., Xiong, Y., Uys, J., & Townsend, D. M. The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer. *Free Radical Biology and Medicine*, 51(2), 229-31.
- [75] Thom, R., Cummins, I., Dixon, D. P., Edwards, R., Cole, D. J., & Lapthorn, A. J. (2002). Structure of a Tau class glutathione S-transferase from wheat active in herbicide detoxification. Structure of a Tau class glutathione S-transferase from wheat active in herbicide detoxification. *Biochemistry*, 41(22), 7008-7020.
- [76] Thornalley, P.J. (1993). The glyoxalase system in health and disease. *Mol Aspects Med*, 14, 287-371.
- [77] Todorova, T. (2007). Glutathione S-transferases and oxidative stress in *Saccharomyces cerevisiae*. Thesis. A cotutelle project between the University Louis Pasteur, Strasbourg and the Sofia University St. Kliment Ohridski. France.
- [78] Umasuthan, N., Revathy, K. S., Lee, Y., Whang, I., Choi, C. Y., & Lee, J. (2012). A novel molluscan sigma-like glutathione S-transferase from Manila clam, *Ruditapes philippinarum*: Cloning, characterization and transcriptional profiling. *Toxicology & Pharmacology*, 155(4), 539-550.
- [79] Van Vleet, T. R., Mace, K., & Coulombe Jr, R. A. (2002). Comparative aflatoxin B1 activation and cytotoxicity in human bronchial cells expressing cytochromes P450 1A2 and 3A4. *Cancer Research*, 62, 105-112.
- [80] Verma, R. J. (2004). Aflatoxin cause DNA damage. *Int j Hum Genet.*, 4(4), 231-236.
- [81] Vuilleumier, S. (1997). Bacterial glutathione S-transferases: What are they good for? *Journal of Bacteriology*, 179, 1431-1441.
- [82] Waxman, D. J. (1990). Glutathione S-transferase: Role in Alkylating agent resistance and possible target for modulation chemotherapy. A review. *Cancer*, 50, 6449-6454.
- [83] World Health Organization International Agency for Research on Cancer (IARC). (1993). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.
- [84] Xu, C., Yong-Tao, C., & Kong, A. T. (2005). Induction of Phase I, II and III Drug Metabolism/Transport by Xenobiotics. *Arch Pharm Res*, 28(3), 249-268.
- [85] Yamuna, A., Saravana, Bhavan. P., & Geraldine, P. (2012). Glutathione S-transferase and metallothionein levels in the freshwater prawn *Macrobrachium melcolmsonii* exposed to mercury. *J. Environ. Biol*, 33, 133-137.
- [86] Yu, J., Bhatnagar, D., & Cleveland, T. E. (2004). Completed sequence of aflatoxin pathway gene cluster in *Aspergillus parasiticus*. *FEBS Lett*, 564, 126-30.
- [87] Yu, S. J. (1996). Insect glutathione S-transferases- Review article. *Zoological Studies*, 35, 9-19.
- [88] Ziglari, T., Allameh, A., Razzaghi-Abyaneh, M., Khosravi, A. R., & Yadegari, M. H. (2008). Comparison of glutathione S-transferase activity and concentration in aflatoxin-producing and their non-toxicogenic counterpart isolates. *Mycopathologia*, 166, 219-226.